Genmab — Oktober 2018
-
Huge New trial, D-RVd, 690 patients Ph III, SC,
https://clinicaltrials.gov/ct2/show/NCT03710603?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=10%2F18%2F2018&rank=3 -
this was Griffin https://clinicaltrials.gov/ct2/show/NCT02874742?term=MMY2004&rank=2
and this one was announce in the summer https://clinicaltrials.gov/ct2/show/NCT03652064?term=Daratumumab+VELCADE+Lenalidomide+Dexamethasone&rank=2 -
this Ofatumumab RMS -autoinjector trial started recruiting https://clinicaltrials.gov/ct2/history/NCT03560739?A=1&B=2&C=merged
-
the JNJ BCMA CD3 DuoBody is near primary completion date on Nov 1; they moved the final completion date to Oct 2019 ; 1 year earlier https://clinicaltrials.gov/ct2/history/NCT03145181?A=10&B=11&C=merged
-
Jeg har desværre en meget sørgelig meddelelse: Analytiker og redaktør for ØU og Nordic Biotech og tidligere flerårig flittig anonym skribent på de sociale aktiemedier Peter Aabo er sidste torsdag 43 år gammel afgået pludseligt ved døden pga en blodprop. Vi er mange her fra PI som har skrevet i samme tråde som ham og nydt godt af hans venlighed og kompetencer indenfor biotek - og pharmaindustrien. Mine tanker går til hans datter og til resten af den nære familie.
-
Bisættelsen fandt sted i eftermiddag. RIP Peter Aabo.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind